ArriVent BioPharma's three largest insider shareholders as of March 23, 2026 are Investment Management, Ltd. Hillhouse (TenPercentOwner, 3.93Mn shares), James Healy (Director, 1.70Mn shares), Carl L Gordon (Director, 1.51Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Investment Management, Ltd. Hillhouse | 0 | 3,929,117 | 03 Feb, 2026 | |
| James Healy | 0 | 1,696,752 | 31 Jan, 2024 | |
| Carl L Gordon | 0 | 1,513,664 | 31 Jan, 2024 | |
| Advisors Llc Orbimed | 0 | 1,513,664 | 31 Jan, 2024 | |
| Robin Lachapelle | Chief Operating Officer | 135,736 | 0 | 15 Jul, 2025 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 02 Feb, 2026 | Robin Lachapelle | Stock Option (right to buy) | A | 130,000 | $0.00 | 130,000 | D | A |
| 02 Feb, 2026 | Zhengbin Yao | Stock Option (right to buy) | A | 550,000 | $0.00 | 550,000 | D | A |
| 02 Feb, 2026 | James Paul Kastenmayer | Stock Option (right to buy) | A | 130,000 | $0.00 | 130,000 | D | A |
| 02 Feb, 2026 | Stuart Lutzker | Stock Option (right to buy) | A | 150,000 | $0.00 | 150,000 | D | A |
| 02 Feb, 2026 | Winston Kung | Stock Option (right to buy) | A | 140,000 | $0.00 | 140,000 | D | A |
| 10 Dec, 2025 | Investment Management, Ltd. Hillhouse | Common Stock | D | 555,555 | $23.37 | 3,929,117 | I | S |
| 11 Jul, 2025 | Robin Lachapelle | Common Stock | A | 2,050 | $2.28 | 126,633 | D | M |
| 11 Jul, 2025 | Robin Lachapelle | Common Stock | A | 2,600 | $2.28 | 129,233 | D | M |
| 11 Jul, 2025 | Robin Lachapelle | Common Stock | A | 6,503 | $2.28 | 135,736 | D | M |
| 11 Jul, 2025 | Robin Lachapelle | Stock Option (right to buy) | D | 2,050 | $0.00 | 410 | D | M |
| 11 Jul, 2025 | Robin Lachapelle | Stock Option (right to buy) | D | 2,600 | $0.00 | 12,873 | D | M |
| 11 Jul, 2025 | Robin Lachapelle | Stock Option (right to buy) | D | 6,503 | $0.00 | 6,370 | D | M |
| 18 Jun, 2025 | John Hohneker | Non-Qualified Stock Option (right to buy) | A | 15,502 | $0.00 | 15,502 | D | A |
| 18 Jun, 2025 | Kristine Peterson | Non-Qualified Stock Option (right to buy) | A | 15,502 | $0.00 | 15,502 | D | A |
| 18 Jun, 2025 | Chris Nolet | Non-Qualified Stock Option (right to buy) | A | 15,502 | $0.00 | 15,502 | D | A |
| 18 Jun, 2025 | Merdad Parsey | Non-Qualified Stock Option (right to buy) | A | 15,502 | $0.00 | 15,502 | D | A |
| 28 Apr, 2025 | Merdad Parsey | Stock Option (right to buy) | A | 28,346 | $0.00 | 28,346 | D | A |
| 03 Feb, 2025 | Zhengbin Yao | Stock Option (right to buy) | A | 380,000 | $0.00 | 380,000 | D | A |
| 03 Feb, 2025 | James Paul Kastenmayer | Stock Option (right to buy) | A | 102,000 | $0.00 | 102,000 | D | A |
| 03 Feb, 2025 | Winston Kung | Stock Option (right to buy) | A | 120,000 | $0.00 | 120,000 | D | A |